HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Summit Therapeutics and raised the price target from $30 to $45, indicating a positive outlook for the company's stock.
September 16, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Summit Therapeutics and increased the price target from $30 to $45, suggesting a positive short-term outlook for the stock.
The increase in the price target from $30 to $45 by HC Wainwright & Co. indicates a strong positive sentiment towards Summit Therapeutics. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100